The aim of the prospective observational DISTEMI-Study in people with and without Diabetes mellitus (DI) after new onset of ST-Segment Elevation Myocardial Infarction (STEMI) aged 18-80 years at inclusion into the study is to characterize in detail the clinical, metabolical, immunological and vascular phenotype, investigate the interplay between myocardial remodelling and the metabolic phenotype, monitor the progression of the disease and compare the phenotype of STEMI people with diabetes mellitus to people with prediabetes and glucose tolerant people.
Condition after new onset of ST-segment elevation myocardial infarction (STEMI)
Age 18-80 years
HbA1c <9.0%
People with diagnosis of diabetes mellitus according to ADA and DDG criteria (i.e. HbA1c ≥6.5% and/or pathological oral glucose tolerance test)
Diabetes mellitus category 3 A-H (ADA criteria), gestational diabetes
Current pregnancy
Infectious diseases, acute infections / fever
Immunosuppressive therapy
Maximum care hospital: Department of Cardiology, Pumonology and Vascular Medicine at University Hospital Düsseldorf (UKD), Heinrich Heine University (HHU), Düsseldorf. People with STEMI are recruited by screening at the German Diabetes Center (GDC/DDZ), Institute for Clinical Diabetology, Leibniz Institute for Diabetes Research at HHU Düsseldorf.
Case-control
Prospective
Not listed
Change of cardiac function
Measurement of left-ventricular ejection fraction by cardiac magnetic resonance (MR) imaging
Change of insulin sensitivity (M-Value)
Measurement of whole body insulin sensitivity with hyperinsulinemic euglycemic clamp (HEC)
Change of insulin secretion
Measurement of beta-cell function with oral and intravenous glucose tolerance test
Change of ectopic fat distribution
Measurement of cardiac and hepatic lipid content by MR spectroscopy (MRS)
Change of liver stiffness
Measurement of liver stiffness by transient elastography (Fibroscan®) and MR elastography (MRE)
Click on the lead sponsor to view all of their trials.
